ARRY-382   Click here for help

GtoPdb Ligand ID: 9108

Synonyms: ARRY 382 | ARRY382 | c-Fms-IN-12 | PF-07265804 | PF07265804
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: ARRY-382 is an investigational, orally administered small molecule inhibitor of the receptor tyrosine kinase, CSF1R (Fms).
The chemical structure shown here was reproduced from Offringa et al. (2022) [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 88.37
Molecular weight 564.68
XLogP 1.23
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC1=CC=CC(=N1)CN2C3=C(C(=CC=C3)NC(=O)C4=CN=C5C=C(C=CN45)OCCN6CCN(C)CC6)C(=N2)C7CC7
Isomeric SMILES CN1CCN(CCOC2=CC3=NC=C(N3C=C2)C(=O)NC4=CC=CC5=C4C(=NN5CC6=NC(C)=CC=C6)C7CC7)CC1
InChI InChI=1S/C32H36N8O2/c1-22-5-3-6-24(34-22)21-40-27-8-4-7-26(30(27)31(36-40)23-9-10-23)35-32(41)28-20-33-29-19-25(11-12-39(28)29)42-18-17-38-15-13-37(2)14-16-38/h3-8,11-12,19-20,23H,9-10,13-18,21H2,1-2H3,(H,35,41)
InChI Key JUPOTOIJLKDAPF-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
A dose escalating clinical trial in patients with selected advanced or metastatic cancers (NCT01316822) has been completed. The record relating to this trial on the ClinicalTrials.gov website was last updated/verified in 2012. More recently Phase 1/2 trial NCT02880371 has begun, to evaluate ARRY-382 in combination with anti-PD-1 checkpoint inhibitor pembrolizumab in adult patients with selected advanced solid tumours.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Colony stimulating factor (CSF) 1 drives macrophage-mediated immune suppression in the tumour microenvironment. CSF1R inhibitors, such as ARRY-382 bind to and inhibit the activity of CSF1R. This compound is therefore predicted to inhibit tumour cell proliferation in CSF1R-overexpressing tumours, by inhibiting activity of tumour-associated macrophages (TAMs). CSF-1 plays an essential role in macrophage differentiation and proliferation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01316822 A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers Phase 1 Interventional Array BioPharma
NCT02880371 A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Phase 1/Phase 2 Interventional Array BioPharma